Monday, 08 March 2021

Insilico and APRINOIA to discover next-gen compounds for neurodegenerative diseases using AI

31 December 2020 | News

Aims to discover novel imaging PET tracers to quantify and visualize pathologies of abnormal proteins in the brain using proprietory AI platforms

Photo Credit: PRNewswire

Photo Credit: PRNewswire

Insilico Medicine has announced that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico's novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compounds targeting abnormal proteins in brain associated with neurodegenerative diseases.

With a mission to accelerate drug discovery and development, Insilico Medicine has been breaking new grounds with its next-generation AI technologies and expanding international partnerships in the US, Europe and Asia Pacific Region.

"APRINOIA discovers and develops first-in-class diagnostics and therapeutics that can be broadly applied as PET tracers in the field of neurodegenerative diseases. We are glad to collaborate with APRINOIA, where we will apply our Chemistry42 suite to design a new generation of PET tracers with desired properties. Through this collaboration, we will further demonstrate the universality of our AI-powered generative chemistry platform," said Jimmy Yen-Chu Lin, PhD, CEO of Insilico Medicine Taiwan.

"We are excited to initiate the collaboration with Insilico to enrich APRINOIA's proprietary collection of compounds for neurodegeneration," said Dr. Ming-Kuei Jang, CEO of APRINOIA. "Early diagnosis is critical for disease management. Our initial focus is to discover novel imaging PET tracers to quantify and visualize pathologies of abnormal proteins in the brain. With Insilico's AI-powered platform, we are hoping to shorten the time from lab to clinics to benefit patients and in the medical communities."

By leveraging an integrated AI-driven drug discovery approach, Insilico Medicine provides APRINOIA Therapeutics with an effective, rational, external auxiliary solution for driving programs forward. The partnership between APRINOIA and Insilico will include an upfront fee and performance-based milestones.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account